Artwork

Content provided by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Becoming All Of Our Selves with Dr. Paula O'Connor, Part II

36:47
 
Share
 

Manage episode 288722832 series 2816013
Content provided by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.

About Dr. Paula O'Connor

Dr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.

Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).

Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.

Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.

Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.

--

New Episodes every Tuesday, available wherever you get your podcasts!

Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!

Sign Up for our newsletter here or at 3BlackDocs.com

A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients.

Learn more about Oncopeptides at https://www.oncopeptides.com/en

Join the Conversation! Follow us on social media!

3 Black Docs

facebook.com/3blackdocs
twitter.com/3blackdocs
instagram.com/3blackdocs
YouTube.com/3blackdocs

Dr. Karen Winkfield

facebook.com/drwinkfield
twitter.com/drwinkfield
instagram.com/drwinkfield

Dr. Zanetta Lamar

facebook.com/drzanetta
instagram.com/drzanetta

  continue reading

94 episodes

Artwork
iconShare
 
Manage episode 288722832 series 2816013
Content provided by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.

About Dr. Paula O'Connor

Dr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.

Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).

Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.

Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.

Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.

--

New Episodes every Tuesday, available wherever you get your podcasts!

Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!

Sign Up for our newsletter here or at 3BlackDocs.com

A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients.

Learn more about Oncopeptides at https://www.oncopeptides.com/en

Join the Conversation! Follow us on social media!

3 Black Docs

facebook.com/3blackdocs
twitter.com/3blackdocs
instagram.com/3blackdocs
YouTube.com/3blackdocs

Dr. Karen Winkfield

facebook.com/drwinkfield
twitter.com/drwinkfield
instagram.com/drwinkfield

Dr. Zanetta Lamar

facebook.com/drzanetta
instagram.com/drzanetta

  continue reading

94 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide